Immunodiagnostics Manufacturers and Market Growth
The global immunodiagnostics market was predicted at US$ 19.1 billion in 2023 and is projected to grow to US$ 70.9 billion by 2034, rising at a compound annual growth rate (CAGR) of 12.84% from 2024 to 2034.
Top Companies in the Immunodiagnostics are:
- Abbott
- NeoGenomics Laboratories
- Thermo Fisher Scientific Inc.
- Agilent Technologies
- QIAGEN
- Hoffmann La Roche AG
- Siemens
- Protagen Protein Services GmbH
- Amarantus Bioscience Holdings Inc.
- Omega Diagnostics Group Plc.
- Nexus-Dx
- Adaptive Biotechnologies
Latest Announcements by Leaders
- In October 2024, Thomas Schinecker, CEO of Roche, announced that the strong growth momentum of the company continued in the third quarter of 2024, which reflects the high demand for innovative medicines and diagnostic solutions of Roche with their positive impact on patient’s lives all over the world.
- In August 2024, Fernando Beils, Senior Vice President and Head of the Molecular Diagnostics Business Area at QIAGEN, announced a partnership with AstraZeneca with the development of QIAstatDx system or genotyping assay to further develop the first companion diagnostic for chronic diseases.
Recent Development in the Immunodiagnostics Market
- In July 2024, Abbott introduced its Alinity c compact clinical chemistry system, which maximizes testing throughput with high-quality assays that deliver accurate and efficient performance. Abbott also introduced its Alinity I compact immunoassay system, which utilizes proven CHEMIFLEX chemiluminescent detection technology to offer greater confidence in test results.
- In September 2024, QIAGEN launched the QIAcuityDx digital PCR system for clinical testing in oncology with its expansion across North America and the European Union.
If you have any questions, please feel free to contact us at
